BFC Planning’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
Other funds holding NKTR
BFC Planning's NKTR Position: Q3 2026 in Review
BFC Planning held its Nektar Therapeutics (NKTR) position steady in Q3 2026 at 158 shares worth $9.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2407.
BFC Planning first reported a position in NKTR in Q3 2024 and has held it in 9 quarters since. The position peaked at $11.4K in Q1 2026. 173 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.
- BFC Planning held 158 shares of Nektar Therapeutics worth $9.6K as of Q3 2026.
- BFC Planning left its Nektar Therapeutics share count unchanged in Q3 2026.
- Nektar Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2407 holding.
- BFC Planning first reported a position in Nektar Therapeutics in Q3 2024 and has held it in 9 quarters since.
- BFC Planning's Nektar Therapeutics position peaked at $11.4K in Q1 2026.
- 173 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.